FUNDAMENTALS · Fundamentals · AU Healthcare

Clinuvel Pharmaceuticals (CUV) Fundamentals 2026 — P/E 15.2x, Revenue Analysis | SniperIQ

Clinuvel Pharmaceuticals (CUV) is a AU-listed Healthcare company in Biotechnology with a market capitalization of A$498M, trading at A$9.88 on the ASX. This SniperIQ fundamentals page covers Clinuvel Pharmaceuticals's valuation (P/E 15.2x, P/B 2.0x), profitability (net margin 33.8%), revenue (A$95M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Market CapA$498M
P/E (TTM)15.2x
Net Margin33.8%
Revenue (FY25)A$95M

Full research coverage

  • 8-Quarter Revenue & Margin Trend
  • Debt Maturity & Coverage
  • Peer Valuation Comparison
  • Free Cash Flow & Owner Earnings
  • AI Signal + Institutional Flow
  • DCF Valuation Model

Frequently Asked Questions

What is Clinuvel Pharmaceuticals's market cap?

Clinuvel Pharmaceuticals (CUV) has a market capitalization of approximately A$498M, trading at A$9.88 on the ASX. Market cap moves with the live share price.

What is Clinuvel Pharmaceuticals's P/E ratio?

Clinuvel Pharmaceuticals's trailing twelve-month P/E ratio is 15.2x, with a price-to-book (P/B) of 2.0x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is Clinuvel Pharmaceuticals?

Clinuvel Pharmaceuticals runs a net profit margin of 33.8%, a gross margin of 63.7%, and an operating margin of 39.4%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does Clinuvel Pharmaceuticals generate?

Clinuvel Pharmaceuticals reported revenue of A$95M for fiscal year 2025, with net income of A

6M and earnings per share (EPS) of 0.72. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does Clinuvel Pharmaceuticals pay a dividend?

Clinuvel Pharmaceuticals offers a trailing dividend yield of about 0.5%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.

Is Clinuvel Pharmaceuticals financially healthy?

Clinuvel Pharmaceuticals carries a debt-to-equity ratio of 0.00x and a current ratio of 14.64x, with a market beta of 0.61. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is Clinuvel Pharmaceuticals a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Clinuvel Pharmaceuticals (CUV) the key facts are: market cap A$498M, P/E 15.2x, revenue A$95M, 52-week range 8.35-14. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track Clinuvel Pharmaceuticals's full fundamentals live

Get Clinuvel Pharmaceuticals's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.